These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38534104)

  • 21. Off-label Use of Long-Acting Injectable Antiretroviral Therapy: A Single Center Retrospective Review of Youth Living With HIV With Detectable HIV RNA Starting Injectable Therapy.
    Rousseau A; McGrath E; Benjamins L; Cockern S; Meade J; Houston K; Breaux M; Secord E
    J Pediatric Infect Dis Soc; 2024 May; 13(5):285-287. PubMed ID: 38591356
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patient Participant Perspectives on Implementation of Long-Acting Cabotegravir and Rilpivirine: Results From the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL) Study.
    Gutner CA; van der Valk M; Portilla J; Jeanmaire E; Belkhir L; Lutz T; DeMoor R; Trehan R; Scherzer J; Pascual-Bernáldez M; Ait-Khaled M; Hernandez B; de Ruiter A; Anand SB; Low EL; Hadi M; Barnes N; Sevdalis N; Mohammed P; Czarnogorski M
    J Int Assoc Provid AIDS Care; 2024; 23():23259582241269837. PubMed ID: 39221544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-acting injectable antiretroviral treatment: experiences of people with HIV and their healthcare providers in Uganda.
    Zakumumpa H; Alinaitwe A; Kyomuhendo M; Nakazibwe B
    BMC Infect Dis; 2024 Aug; 24(1):876. PubMed ID: 39198739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Long-acting injection therapies: New opportunities and challenges].
    Lee M
    MMW Fortschr Med; 2024 Jul; 166(Suppl 2):32-34. PubMed ID: 38980615
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
    Overton ET; Richmond G; Rizzardini G; Jaeger H; Orrell C; Nagimova F; Bredeek F; García Deltoro M; Swindells S; Andrade-Villanueva JF; Wong A; Khuong-Josses MA; Van Solingen-Ristea R; van Eygen V; Crauwels H; Ford S; Talarico C; Benn P; Wang Y; Hudson KJ; Chounta V; Cutrell A; Patel P; Shaefer M; Margolis DA; Smith KY; Vanveggel S; Spreen W
    Lancet; 2021 Dec; 396(10267):1994-2005. PubMed ID: 33308425
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world use of long-acting cabotegravir and rilpivirine: 12-month results of the inJectable Antiretroviral therapy feasiBility Study (JABS).
    John M; Williams L; Nolan G; Bonnett M; Castley A; Nolan D
    HIV Med; 2024 Aug; 25(8):935-945. PubMed ID: 38644518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implementation of long-acting cabotegravir and rilpivirine: primary results from the perspective of staff study participants in the Cabotegravir And Rilpivirine Implementation Study in European Locations.
    Gutner CA; Hocqueloux L; Jonsson-Oldenbüttel C; Vandekerckhove L; van Welzen BJ; Slama L; Crusells-Canales M; Sierra JO; DeMoor R; Scherzer J; Ait-Khaled M; Bontempo G; Gill M; Patel N; D'Amico R; Hove K; Baugh B; Barnes N; Hadi M; Low EL; Anand SB; Hamilton A; Garges HP; Czarnogorski M
    J Int AIDS Soc; 2024 Jul; 27(7):e26243. PubMed ID: 38978405
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potential healthcare resource use and associated costs of every 2 month injectable cabotegravir plus rilpivirine long-acting regimen implementation in the Spanish National Healthcare System compared to daily oral HIV treatments.
    Aparicio LV; García VN; Hernández-Novoa B; Casado G; Jodar F; Pinel M; Velasco DC
    BMC Infect Dis; 2024 Aug; 24(1):775. PubMed ID: 39095714
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents.
    Rajoli RKR; Back DJ; Rannard S; Meyers CF; Flexner C; Owen A; Siccardi M
    Clin Pharmacokinet; 2018 Feb; 57(2):255-266. PubMed ID: 28540638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monthly injectable cabotegravir/rilpivirine to manage HIV infection in adults.
    Blackwell CW; López Castillo H
    J Am Assoc Nurse Pract; 2022 Jul; 34(7):918-923. PubMed ID: 35580282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
    Orkin C; Arasteh K; Górgolas Hernández-Mora M; Pokrovsky V; Overton ET; Girard PM; Oka S; Walmsley S; Bettacchi C; Brinson C; Philibert P; Lombaard J; St Clair M; Crauwels H; Ford SL; Patel P; Chounta V; D'Amico R; Vanveggel S; Dorey D; Cutrell A; Griffith S; Margolis DA; Williams PE; Parys W; Smith KY; Spreen WR
    N Engl J Med; 2020 Mar; 382(12):1124-1135. PubMed ID: 32130806
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long-Acting Intramuscular Injection in Real-World People with HIV.
    Thoueille P; Saldanha SA; Schaller F; Choong E; Veuve F; Munting A; Cavassini M; Braun D; Günthard HF; Duran Ramirez JJ; Surial B; Furrer H; Rauch A; Ustero P; Calmy A; Stöckle M; Di Benedetto C; Bernasconi E; Schmid P; Marzolini C; Girardin FR; Buclin T; Decosterd LA; Guidi M;
    Clin Pharmacol Ther; 2024 Jun; 115(6):1450-1459. PubMed ID: 38519844
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identifying Implementation Determinants and Strategies for Long-Acting Injectable Cabotegravir-Rilpivirine in People With HIV Who Are Virally Unsuppressed.
    Hickey MD; Grochowski J; Mayorga-Munoz F; Oskarsson J; Imbert E; Spinelli M; Szumowski JD; Appa A; Koester K; Dauria EF; McNulty M; Colasanti J; Havlir DV; Gandhi M; Christopoulos KA
    J Acquir Immune Defic Syndr; 2024 Jul; 96(3):280-289. PubMed ID: 38534179
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.
    Swindells S; Andrade-Villanueva JF; Richmond GJ; Rizzardini G; Baumgarten A; Masiá M; Latiff G; Pokrovsky V; Bredeek F; Smith G; Cahn P; Kim YS; Ford SL; Talarico CL; Patel P; Chounta V; Crauwels H; Parys W; Vanveggel S; Mrus J; Huang J; Harrington CM; Hudson KJ; Margolis DA; Smith KY; Williams PE; Spreen WR
    N Engl J Med; 2020 Mar; 382(12):1112-1123. PubMed ID: 32130809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cabotegravir-rilpivirine treatment initiation in a nonvirologically suppressed patient.
    Barnett SK; Armas-Kolostroubis L; Sension M; Riedel DJ
    AIDS; 2022 Aug; 36(10):1475-1476. PubMed ID: 35876710
    [No Abstract]   [Full Text] [Related]  

  • 36. Development of an oral once-weekly drug delivery system for HIV antiretroviral therapy.
    Kirtane AR; Abouzid O; Minahan D; Bensel T; Hill AL; Selinger C; Bershteyn A; Craig M; Mo SS; Mazdiyasni H; Cleveland C; Rogner J; Lee YL; Booth L; Javid F; Wu SJ; Grant T; Bellinger AM; Nikolic B; Hayward A; Wood L; Eckhoff PA; Nowak MA; Langer R; Traverso G
    Nat Commun; 2018 Jan; 9(1):2. PubMed ID: 29317618
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and Effectiveness From the Cabotegravir and Rilpivirine Implementation Study in European Locations Study: Phase 3b Hybrid Type III Implementation Study Integrating Cabotegravir + Rilpivirine Long-Acting Into European Clinical Settings.
    Jonsson-Oldenbüttel C; Ghosn J; van der Valk M; Florence E; Vera F; De Wit S; Rami A; Bonnet F; Hocqueloux L; Hove K; Ait-Khaled M; DeMoor R; Bontempo G; Latham CL; Gutner CA; Iyer S; Gill M; Czarnogorski M; D'Amico R; van Wyk J
    J Acquir Immune Defic Syndr; 2024 Aug; 96(5):472-480. PubMed ID: 38985445
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Perspectives Among Health Care Providers and People with HIV on the Implementation of Long-Acting Injectable Cabotegravir/Rilpivirine for Antiretroviral Therapy in Florida.
    Fisk-Hoffman RJ; Ranger SS; Gracy A; Gracy H; Manavalan P; Widmeyer M; Leeman RF; Cook RL; Canidate S
    AIDS Patient Care STDS; 2024 Jun; 38(6):275-285. PubMed ID: 38686517
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contribution of cabotegravir + rilpivirine long-acting for the treatment of HIV-1 infection.
    Calleja-Hernández MÁ; Martinez-Sesmero JM; Vallejo-Aparicio LA; Hernández-Novoa B; Badia X
    Farm Hosp; 2022 Jul; 46(4):208-214. PubMed ID: 36183218
    [TBL] [Abstract][Full Text] [Related]  

  • 40. What is the significance of the pharmacokinetic profile and potential drug-drug interactions of long-acting intramuscular cabotegravir and rilpivirine?
    Bettonte S; Berton M; Marzolini C
    Expert Opin Drug Metab Toxicol; 2023; 19(5):243-247. PubMed ID: 37293864
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.